N.J. Federal Judge Dismisses Multi-Plaintiff Amiodarone Action



DOCUMENTS
  • Order


TRENTON, N.J. — A New Jersey federal judge has dismissed a multi-plaintiff amiodarone action, ruling the plaintiffs’ claims based upon Aurobindo Pharma USA Inc.’s alleged failure to provide a Medication Guide are impliedly preempted because they exist solely by virtue of the Food, Drug and Cosmetic Act.

On April 27, Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey further ruled that the plaintiffs failed to identify any state law that requires Aurobindo to report adverse events to the Food and Drug Administration.

Wyeth Pharmaceuticals Inc. received FDA approval in 1985 for Cordarone (amiodarone) …






UPCOMING CONFERENCES




HarrisMartin's Midwest Asbestos Litigation Conference

September 21, 2022 - St. Louis, MO
Four Seasons Hotel, St. Louis

MORE DETAILS



HarrisMartin's Camp Lejeune Water Contamination Litigation Conference: What Comes Next?

September 15, 2022 - Houston, TX
Four Seasons Hotel Houston

MORE DETAILS